Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVENT: Enavogliflozin in Functional Tricuspid Regurgitation and HFpEF
NCT06027307Phase 3Active, not recruiting
- Sponsor
- Asan Medical Center
- Start
- Oct 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enavogliflozin in tricuspid regurgitation, heart failure with preserved ejection fraction (HFpEF), sponsored by Asan Medical Center. Started Oct 2023; status: active, not recruiting.
02
Drugs
enavogliflozin
03
Conditions
tricuspid regurgitationheart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06027307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027307.